Figure 3.

(A) Western bloting of p-S6 with or without Everolimus. Everolimus inhibited p-S6, a downstream target of mTOR, in SAS and SAS-R cells. Cells were treated with 1 and 3 nmol/L Everolimus, and cell lysates were collected at 0, 60, and 180 min. (B) Immunohistochemical analysis of p-S6. Three days after each treatment, p-S6 expression was analyzed. p-S6 was detected in endothelial (arrowheads) and tumor cells in SAS and SAS-R tumors. Everolimus completely suppressed p-S6 expression, even after radiation exposure, in endothelial and tumor cells of SAS and SAS-R. mTOR, mammalian target of rapamycin.